Literature DB >> 31964555

Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine.

Anne Derbise1, Chloé Guillas1, Christiane Gerke2, Elisabeth Carniel1, Javier Pizarro-Cerdà1, Christian E Demeure3.   

Abstract

A single oral inoculation to mice of the live attenuated Yersinia pseudotuberculosis VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 108 CFU induced dose-dependent antibody production. At the dose of 107 CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of Yersinia pestis. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bubonic plague; Live vaccine; Pneumonic plague; Subcutaneous; Yersinia pestis; Yersinia pseudotuberculosis

Mesh:

Substances:

Year:  2020        PMID: 31964555     DOI: 10.1016/j.vaccine.2020.01.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Experimental Nanovaccine Offers Protection Against Repeat Exposures to Trypanosoma cruzi Through Activation of Polyfunctional T Cell Response.

Authors:  Imran H Chowdhury; Nandadeva Lokugamage; Nisha Jain Garg
Journal:  Front Immunol       Date:  2020-12-22       Impact factor: 7.561

Review 2.  Dangerous Pathogens as a Potential Problem for Public Health.

Authors:  Edyta Janik; Michal Ceremuga; Marcin Niemcewicz; Michal Bijak
Journal:  Medicina (Kaunas)       Date:  2020-11-06       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.